Efficacy and safety of biological agents for the treatment of pediatric patients with psoriasis: A bayesian analysis of six high-quality randomized controlled trials

Abstract

BackgroundBiological agents have been used with extreme caution in children because of their possible adverse effects.ObjectivesThis study used high-quality randomized controlled trials (RCTs) to provide high-level evidence to assess the effectiveness and safety of biological agents for treating children with psoriasis.MethodsWe searched PubMed, Embase, Cochrane, and Web of Science databases through October 31, 2021. We included trials reporting at least one adverse event after treatment with biological agents of patients less than 18-year-old diagnosed with psoriasis. RevMan 5.3 and Stata 15.0 software were used for meta and Bayesian analyses.ResultsSix trials with 864 participants were included in the analysis. The results showed a 2.37-fold higher response rate in all biologics groups than in the control group for psoriasis area and severity index 75 (PASI75) (RR= 2.37, P-value < 0.01, 95% confidence interval [CI] [1.22, 4.62]). Compared with placebo, the PASI75 response rates of etanercept (RR= 2.82, 95% [CI] [1.10, 7.21]), ustekinumab low dose (RR= 7.45, 95%[CI] [1.25, 44.58]), and ustekinumab high dose (RR= 7.25, 95%[CI] [1.21, 43.41]) were superior. Additionally, the incidence of total adverse reactions was 1.05 times higher for biologics than for controls, indicating a good safety profile (RR= 1.05, P-value = 0.53, 95%[CI] [0.92, 1.19]). Overall, these six high-quality randomized controlled trials suggest that biologics are effective and safe for pediatric patients with psoriasis.LimitationsInclusion of few relevant, high-quality RCTs.ConclusionThe results of this study indicate that biologics can be used to treat children with moderate-to-severe psoriasis without the risk of adverse effects. Ustekinumab showed the best efficacy and the fewest adverse effects.

Genetically engineered biologics to treat psoriasis. Experience with ustekinumab in an adolescent with severe psoriasis

“…Более того, в настоящее время среди дерматологов все больше сторонников того, что генно-инженерные биологические препараты (устекинумаб, секукинумаб, адалимумаб, иксекизумаб, этанерцепт) могут назначаться как средства первой линии для лечения среднетяжелого и тяжелого псориаза у детей и подростков. Такая точка зрения, в частности, отражена в итальянском консенсусе 2022 г. как практическая рекомендация для врачей [13][14][15][16][17][18].…”

Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability

“… 35 However, due to lack of long-term results of head-to-head studies, it is still unknown which biologic treatment should be primarily used in treatment for pediatric patients with PsO. 36 …”

Treatment of skin defects with PRP enriched with hyaluronic acid – histological aspects in rat model

“…Skin disease diagnosis and treatment have advanced significantly over the past few decades due to the contributions of doctors and researchers. So, the development and use of a wide range of medications and dressings, skin grafts, and certain biological agents have greatly expanded the ways that acute and chronic skin lesions can be treated [ 7 , 8 , 9 , 10 ]. In the past two decades, platelet-rich plasma (PRP) has been utilized experimentally and therapeutically to treat a variety of skin conditions.…”